$0.59
6.10%
Nasdaq, Nov 20, 03:59 pm EST. Closed.
ISIN
US2075231017
Symbol
CNTB

Connect Biopharma Holdings Ltd - ADR Stock price

$0.59
-0.29 32.59% 1M
-1.72 74.46% 6M
-2.23 79.08% YTD
-2.56 81.27% 1Y
-1.47 71.36% 3Y
-4.10 87.42% 5Y
-16.41 96.53% 10Y
-16.41 96.53% 20Y
Nasdaq, Closing price Fri, Nov 20 2026
-0.04 6.08%
ISIN
US2075231017
Symbol
CNTB
Industry

Is Connect Biopharma Holdings Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$38.1m
Enterprise Value
$6.6m
Net debt
positive
Cash
$31.5m
Shares outstanding
63.0m
Valuation
P/E
negative
P/S | estimate
12.9 | 4.6
EV/Sales | estimate
2.2 | 0.8
EV/FCF | ex SBC
negative | negative
P/B
1.4
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-259.2%
ROIC
-708.3%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$4.3m | 145.4%
SBC as % of FCF
-
SBC Growth 1Y
127.0%
Share Count Growth 1Y
13.3%
Shareholder Yield
-13.3%
Financials
Revenue | estimate
$3.0m | $8.3m
EBITDA
$-69.7m
EBIT
$-70.4m
Net Income
$-69.0m
Free Cash Flow | ex SBC
$-60.6m | $-64.9m
Growth
Revenue | estimate
-88.7% | 13,743.3%
EBITDA
-97.3%
EBIT
-96.3%
Net Income
-141.8%
Free Cash Flow
-55.9%
Margin
Gross
-
EBITDA
-2,361.3%
EBIT
-2,384.5%
Net
-2,336.3%
Free Cash Flow | ex SBC
-2,053.3% | -2,198.7%
More
EPS
$-1.1
FCF per Share
$-1.0
Short interest
8.3%
Employees
62
Rev per Employee
$0.0

Connect Biopharma Holdings Ltd - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

Buy
92%
Hold
8%

Connect Biopharma Holdings Ltd - ADR Events

Past Events
NOV
16
Q3 2026 Earnings Call
6 days ago
OCT
21
Special Call - Connect Biopharma Holdings Limited (Inactive)
about one month ago
SEP
30
Special Call - Connect Biopharma Holdings Limited (Inactive)
about 2 months ago
SEP
15
Special Call - Connect Biopharma Holdings Limited (Inactive)
2 months ago
MAR
30
Special Call - Connect Biopharma Holdings Limited
8 months ago
NOV
3
Special Call - Connect Biopharma Holdings Limited
about one year ago

Financial data from Connect Biopharma Holdings Ltd - ADR

Jun '26
+/-
%
2.95 2.95
89% 89%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
13% 13%
667%
- Research and Development Expense 54 54
44% 44%
1,820%
-70 -70
97% 97%
-2,364%
- Depreciation and Amortization 0.69 0.69
30% 30%
23%
EBIT (Operating Income) EBIT -70 -70
96% 96%
-2,387%
Net Profit -69 -69
142% 142%
-2,339%

In millions USD.

Don't miss a Thing! We will send you all news about Connect Biopharma Holdings Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Connect Biopharma Holdings Ltd - ADR Stock News

Neutral
GlobeNewsWire
●
6 days ago
– Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) –
Neutral
GlobeNewsWire
●
about 2 months ago
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –
Neutral
GlobeNewsWire
●
2 months ago
– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to placebo – – Rademikibart was well tolerated in asthma patients experiencing an acute exacerbation with a low incidence of adverse events– – Data from Seabreeze STAT COPD study of rade...
More Connect Biopharma Holdings Ltd - ADR News

Company Profile

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Head office Cayman Islands
CEO Dr. Quart
Employees 62
Founded 2015
Website www.connectbiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today